Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 8, 199 (2002)
doi:10.1038/nm0302-199a
Promising drug is victim of bad business
Alan Dove1
- Philadelphia
It's disappointing to see any medicine fail in clinical trials: patient hopes are dashed, drug companies lose out on their investment and scientists have to return to the drawing board. The setback in trials of colon cancer drug Erbitux provides a poignant example of the first two conditions, but, conversely, it is also an example of successful biomedical research.
To read this story in full you will need to login or make a payment (see right).
